A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)

Inclusion Criteria:

• The participant has a diagnosis of cCH as defined by International Headache Society (IHS) International Classification of Headache Disorders third edition (ICHD-3)classification with a history of cCH of at least 12 months prior to the ScreeningVisit.

• The participant has a medical history of onset of cluster headache at ≤50 years ofage.

• The participant has an adequately documented record of previous abortive,transitional and preventive medication use for cCH, for at least 12 months prior tothe Screening Visit.

• The participant is able to distinguish cluster headache attacks from other headaches (such as tension-type headaches, migraine).

Exclusion Criteria:

• The participant has experienced failure on a previous treatment targeting thecalcitonin gene-related peptide (CGRP) pathway (anti-CGRP monoclonal antibodies [mAbs] and gepants).

• The participant has confounding and clinically significant pain syndromes (forexample, fibromyalgia, complex regional pain syndrome).

• The participant has a history or diagnosis of chronic tension-type headache, hypnicheadache, hemicrania continua, new daily persistent headache, chronic migraine orunusual migraine subtypes such as hemiplegic migraine (sporadic and familial),recurrent painful ophthalmoplegic neuropathy, migraine with neurologicalaccompaniments that are not typical of migraine aura (diplopia, alteredconsciousness, or longer than 1 hour).

• Participants with a lifetime history of psychosis, bipolar mania, or dementia.Participants with other psychiatric conditions whose symptoms are not controlled orwho have not been adequately treated for a minimum of 6 months prior to ScreeningVisit.

• The participant has attempted suicide or is, at Screening Visit, at significant riskof suicide.

• The participant has a history of clinically significant cardiovascular disease,including uncontrolled hypertension, vascular ischaemia or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonaryembolism).

Other inclusion and exclusion criteria may apply.